Cargando…

Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus

OBJECTIVES: The objective of the study was to evaluate the effect of metformin alone or in combination with coenzyme Q10 (CoQ10) on inflammatory changes and endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: A total numbers of 54 patients with T2DM compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Kuraishy, Hayder M., Al-Gareeb, Ali I., Shams, Hala A., Al-Mamorri, Farah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943859/
https://www.ncbi.nlm.nih.gov/pubmed/31929697
http://dx.doi.org/10.4103/JLP.JLP_123_19
_version_ 1783484963663904768
author Al-Kuraishy, Hayder M.
Al-Gareeb, Ali I.
Shams, Hala A.
Al-Mamorri, Farah
author_facet Al-Kuraishy, Hayder M.
Al-Gareeb, Ali I.
Shams, Hala A.
Al-Mamorri, Farah
author_sort Al-Kuraishy, Hayder M.
collection PubMed
description OBJECTIVES: The objective of the study was to evaluate the effect of metformin alone or in combination with coenzyme Q10 (CoQ10) on inflammatory changes and endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: A total numbers of 54 patients with T2DM compared to 30 healthy subjects were divided into three groups: Group A (n = 30): healthy subjects without any medications; Group B (n = 24): T2DM patients treated with metformin 1 g/day; and Group C (n = 30): T2DM patients treated with metformin 1 g/day plus CoQ10, 300 mg/day. The duration of the study was 8 weeks. Fasting blood glucose, glycated hemoglobin, lipid profile, blood pressure variables, fasting insulin, insulin resistance, homeostatic model assessment of insulin resistance, vascular cell adhesion molecule 1 (VCAM-1), and E-selectin were measured before and after therapy. RESULTS: Metformin and/or CoQ10 therapy illustrated an insignificant effect on the fody mass index. This combination produced a significant improvement of metabolic changes in patients with T2DM (P < 0.01). sVCAM-1 serum level was decreased significantly after the initiation of metformin and/or CoQ10 therapy compared to the baseline P < 0.05. E-selectin was declined significantly following metformin monotherapy and after metformin plus CoQ10 therapy (P = 0.0001). CONCLUSION: CoQ10 add-on metformin therapy improves endothelial dysfunction and inflammatory changes in patients with T2DM alongside with amelioration of metabolic profile.
format Online
Article
Text
id pubmed-6943859
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-69438592020-01-10 Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus Al-Kuraishy, Hayder M. Al-Gareeb, Ali I. Shams, Hala A. Al-Mamorri, Farah J Lab Physicians Original Article OBJECTIVES: The objective of the study was to evaluate the effect of metformin alone or in combination with coenzyme Q10 (CoQ10) on inflammatory changes and endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: A total numbers of 54 patients with T2DM compared to 30 healthy subjects were divided into three groups: Group A (n = 30): healthy subjects without any medications; Group B (n = 24): T2DM patients treated with metformin 1 g/day; and Group C (n = 30): T2DM patients treated with metformin 1 g/day plus CoQ10, 300 mg/day. The duration of the study was 8 weeks. Fasting blood glucose, glycated hemoglobin, lipid profile, blood pressure variables, fasting insulin, insulin resistance, homeostatic model assessment of insulin resistance, vascular cell adhesion molecule 1 (VCAM-1), and E-selectin were measured before and after therapy. RESULTS: Metformin and/or CoQ10 therapy illustrated an insignificant effect on the fody mass index. This combination produced a significant improvement of metabolic changes in patients with T2DM (P < 0.01). sVCAM-1 serum level was decreased significantly after the initiation of metformin and/or CoQ10 therapy compared to the baseline P < 0.05. E-selectin was declined significantly following metformin monotherapy and after metformin plus CoQ10 therapy (P = 0.0001). CONCLUSION: CoQ10 add-on metformin therapy improves endothelial dysfunction and inflammatory changes in patients with T2DM alongside with amelioration of metabolic profile. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6943859/ /pubmed/31929697 http://dx.doi.org/10.4103/JLP.JLP_123_19 Text en Copyright: © 2019 Journal of Laboratory Physicians http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Al-Kuraishy, Hayder M.
Al-Gareeb, Ali I.
Shams, Hala A.
Al-Mamorri, Farah
Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus
title Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus
title_full Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus
title_fullStr Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus
title_full_unstemmed Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus
title_short Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus
title_sort endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme q10 add-on metformin in patients with type 2 diabetes mellitus
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943859/
https://www.ncbi.nlm.nih.gov/pubmed/31929697
http://dx.doi.org/10.4103/JLP.JLP_123_19
work_keys_str_mv AT alkuraishyhayderm endothelialdysfunctionandinflammatorybiomarkersasaresponsefactorofconcurrentcoenzymeq10addonmetformininpatientswithtype2diabetesmellitus
AT algareebalii endothelialdysfunctionandinflammatorybiomarkersasaresponsefactorofconcurrentcoenzymeq10addonmetformininpatientswithtype2diabetesmellitus
AT shamshalaa endothelialdysfunctionandinflammatorybiomarkersasaresponsefactorofconcurrentcoenzymeq10addonmetformininpatientswithtype2diabetesmellitus
AT almamorrifarah endothelialdysfunctionandinflammatorybiomarkersasaresponsefactorofconcurrentcoenzymeq10addonmetformininpatientswithtype2diabetesmellitus